A	B	C
1	Main
2		Brand Name	ALKS33
3		Generic Name
4		Indication	Addiction and other CNS disorders
5		Mechanism	"Opioid modulator". Likely antagonist as naltrexone is a mu-antagonist.
6		Administration	Oral
7		Origin	identified from a family of compounds in-licensed from Rensselaer Polytechnic Institute. Ron Kulda, Tech Transfer Office at RPI. Mark Wentland and Jean Bidlack were the scientists at RPI.
8		Economics	September 2006 licensed a family of compounds from RPI. Will owe royalties and milestones.
9		Clinical Trials
10			Phase II - scheduled to begin by YE09
11
12
13			Phase I ALKS33-003 n=30
14
15			Phase I ALKS33-004 n=24
16
17			Phase I n=16 SAD - initiated December 2008
18
19
20
21			Preclinical vs naltrexone
22			35-50% reduction in drinking vs 10% for naltrexone